DS1025 Enters Clinical Development in Patients with Advanced Solid Tumors as Novel CD25 Directed ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo

Phase 1DS1025Positive

AI Analysis

Summary

Daiichi Sankyo announced that DS1025, a novel CD25-directed antibody-drug conjugate (ADC), has entered clinical development in patients with advanced solid tumors as part of the company's ADC portfolio.

Clinical Trial Data

Phase

Importance:5/10

Sentiment:

0.30

ADCCD25oncologyclinical developmentsolid tumors

Related Companies

$DSKYF

Read the original article

Published by yahoo_finance on August 27, 2026 11:00 AM

Read Original